Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | IKBKB | O14920 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.44 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.44 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.44 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23301214 | 0.98 | HRH1 (0.61) | HRH1SLC6A4SLC6A2SLC6A3IKBKB | |
| SCHEMBL1416985 | 0.87 | SLC6A4 (0.67) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29711702 | 0.87 | SLC6A4 (0.67) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL29735165 | 0.84 | SLC6A4 (0.63) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL30124975 | 0.84 | SLC6A2 (0.63) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1337657 | 0.84 | SLC6A2 (0.63) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1438129 | 0.84 | SLC6A4 (0.63) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2320394 | 0.82 | SLC6A2 (0.61) | HRH1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11073457 | 0.81 | IKBKB (0.60) | HRH1IKBKBROCK1ROCK2PRKACA | |
| SCHEMBL61407 | 0.81 | HRH1 (0.65) | HRH1IKBKBHTR6ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3902556-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | Vividion Therapeutics, Inc. (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10869860-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2020140039-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3209664-B1 | BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
| EP-2766352-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (UHN) (CA) | 2014-08-20 | — | — | EP | disclosed |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERISTY HEALTH NETWORKS (CA) | 2014-02-20 | — | — | US | disclosed |
| WO-2013053051-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-18 | — | — | WO | disclosed |
| EP-1626958-B1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | LILLY CO ELI (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-05-07 | — | — | US | disclosed |
| EP-1910352-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | SCD, SCD5, SREBF1 | HRH1 3088/4885SLC6A4 4235/4885SLC6A2 4249/4885 |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885SLC6A4 4055/4885SLC6A2 4588/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885SLC6A4 4055/4885SLC6A2 4588/4885 |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | HRH1 4404/4885SLC6A4 3443/4885SLC6A2 4715/4885 |
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | HRH1 4198/4885SLC6A4 2223/4885SLC6A2 2784/4885 |
| US-10869860-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | HRH1 4198/4885SLC6A4 2223/4885SLC6A2 2784/4885 |
| US-20140051679-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K7, MAP3K1, MAP3K20 | HRH1 4114/4885SLC6A4 2987/4885SLC6A2 2706/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885SLC6A4 4055/4885SLC6A2 4588/4885 |
| US-20200206201-A1 | CEREBLON MODULATORS AND USES THEREOF | CRBN, CBFB, CNN2 | HRH1 4198/4885SLC6A4 2223/4885SLC6A2 2784/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | HRH1 4569/4885SLC6A4 4055/4885SLC6A2 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.